Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E143.40 EPS (ttm)1.03 Insider Own0.50% Shs Outstand243.53M Perf Week-3.67%
Market Cap36.07B Forward P/E48.82 EPS next Y3.03 Insider Trans-52.45% Shs Float243.53M Perf Month-7.03%
Income259.50M PEG2.10 EPS next Q0.30 Inst Own99.80% Short Float1.50% Perf Quarter25.51%
Sales2.13B P/S16.93 EPS this Y80.10% Inst Trans1.09% Short Ratio1.78 Perf Half Y67.70%
Book/sh6.75 P/B21.95 EPS next Y89.63% ROA8.80% Target Price178.09 Perf Year49.48%
Cash/sh6.85 P/C21.62 EPS next 5Y68.24% ROE19.40% 52W Range71.46 - 167.85 Perf YTD101.07%
Dividend- P/FCF60.10 EPS past 5Y-39.40% ROI-0.30% 52W High-11.75% Beta1.78
Dividend %- Quick Ratio3.30 Sales past 5Y3.80% Gross Margin89.20% 52W Low107.29% ATR4.70
Employees2150 Current Ratio3.50 Sales Q/Q26.10% Oper. Margin16.20% RSI (14)47.21 Volatility1.98% 2.77%
OptionableYes Debt/Eq0.34 EPS Q/Q127.10% Profit Margin12.20% Rel Volume0.43 Prev Close148.54
ShortableYes LT Debt/Eq0.33 EarningsJul 26 AMC Payout0.00% Avg Volume2.05M Price148.13
Recom1.80 SMA20-4.68% SMA505.36% SMA20039.00% Volume887,138 Change-0.28%
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Jan-26-17Reiterated Stifel Buy $108 → $100
Dec-15-16Initiated Oppenheimer Perform
Oct-24-16Downgrade H.C. Wainwright Buy → Neutral $85
Sep-15-16Reiterated Stifel Buy $105 → $109
Sep-13-16Initiated Raymond James Mkt Perform
Aug-16-16Reiterated Stifel Buy $108 → $105
Apr-28-16Reiterated RBC Capital Mkts Outperform $135 → $115
Apr-28-16Reiterated Barclays Overweight $135 → $110
Aug-17-17 09:03AM  The 3 Best Stocks in Healthcare Motley Fool
Aug-16-17 08:00AM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
Aug-15-17 05:20PM  ETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017 Capital Cube
04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 10:25AM  Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isnt Worth the Risk InvestorPlace
Aug-13-17 08:00AM  Edited Transcript of VRTX earnings conference call or presentation 26-Jul-17 9:15pm GMT Thomson Reuters StreetEvents
Aug-11-17 11:44AM  CD 2016-CD1 Mortgage Trust -- Moody's Affirms Eight Classes of CD 2016-CD1 Moody's
08:04AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Aug-10-17 08:04AM  IHS Markit Score downgrades Vertex Pharmaceuticals Inc to 64 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
09:45AM  For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another? Forbes
Aug-04-17 08:01PM  Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings Motley Fool
Aug-03-17 07:45PM  Why Vertex Pharmaceuticals Skyrocketed 17.8% in July Motley Fool
09:46AM  Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons InvestorPlace
07:10AM  Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis ACCESSWIRE
Aug-02-17 12:35PM  Vertexs latest FDA nod could boost sales by $150M: analyst American City Business Journals
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
Aug-01-17 12:09PM  Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
08:01AM  FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations Business Wire
Jul-28-17 10:00AM  Vertex Pharmaceuticals Incorporated Chugs Along Motley Fool
Jul-27-17 04:50PM  Vertex Pharmaceuticals: Looking East, West and to the Quants TheStreet.com
04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
02:50PM  Vertex Pharmaceuticals: Looking East, West and to the Quants TheStreet.com
09:54AM  Zacks.com featured highlights: Farmers & Merchants Bancorp, Advanced Energy Industries, NVR, Vertex Pharmaceuticals and Sanderson Farms Zacks
08:59AM  Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales Zacks
08:06AM  J.P. Morgan Elevates Price Targets on Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) After Glowing 2Q Performance SmarterAnalyst
08:00AM  Trending: Corn Falls Due to Heavy Northeast Rains ETF Database
Jul-26-17 10:55PM  Vertex tops Street 2Q forecasts Associated Press
05:20PM  Vertex Sinks Late Despite Crushing Sales, Profit Expectations Investor's Business Daily
04:28PM  Vertex Pharma's quarterly profit beats estimates Reuters
04:08PM  Vertex Pharma reports quarterly profit Reuters
04:01PM  Vertex Reports Second-Quarter 2017 Financial Results Business Wire
11:15AM  Investor Network: Vertex Pharmaceuticals Incorporated to Host Earnings Call Accesswire
10:39AM  Vertex Pharmaceuticals Focus on Innovative Combination Regimens Market Realist
09:09AM  Why Vertex Pharmaceuticals Could Expand Its Addressable Market Market Realist
07:42AM  Vertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017 Market Realist
06:00AM  Gilead Faces 6th Quarter of Falling Revenue Investopedia
Jul-25-17 05:36PM  Vertex: Why Label Expansion Could Boost Orkambi Sales in 2017 Market Realist
04:06PM  Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand Market Realist
04:01PM  Top Stock Picks for the Week of July 24th Zacks
04:01PM  Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656 Business Wire
02:10PM  Wall Streets Latest Recommendations for Vertex Pharmaceuticals Market Realist
11:18AM  Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK Zacks
08:47AM  Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season Zacks
07:00AM  Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jul-24-17 10:18AM  Top Ranked Momentum Stocks to Buy for July 24th Zacks
09:30AM  Zacks.com featured highlights: Vertex Pharmaceuticals, AGCO, Owens Corning, Five9 and Axcelis Technologies Zacks
08:36AM  Equifax (EFX) to Post Q2 Earnings: What's in the Cards? Zacks
Jul-21-17 04:14PM  Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' Investor's Business Daily
02:46PM  Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings? Zacks
01:38PM  Will Gilead Beat 2Q Earnings? PerhapsBut Does It Matter? Barrons.com
11:23AM  What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings? Zacks
09:46AM  Stock Market News for July 21, 2017 Zacks
08:20AM  Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2% Zacks
03:54AM  5 Stock Picks with Earnings Beat Potential Zacks
Jul-20-17 02:00PM  Vertex Becomes an Overnight Biotech M&A Darling Bloomberg
12:00PM  S&P Stealth Outperformers: Health Care Investopedia
10:19AM  Biotech Stocks on Fire After Vertex News Investopedia
10:01AM  Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock Like Its 20% Gain Never Happened InvestorPlace
09:40AM  Company News for July 20, 2017 Zacks
08:49AM  Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX) SmarterAnalyst
08:20AM  Today's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris Accesswire
12:40AM  [$$] Vertex Shares Havent Hit Their Apex The Wall Street Journal
12:05AM  Asian shares rally, helped by Wall Street, Japan trade data Associated Press
Jul-19-17 05:00PM  GLOBAL MARKETS-World stocks tally 9th day of gains as earnings pick up Reuters +20.83%
04:54PM  What Happened in the Stock Market Today Motley Fool
04:44PM  Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy Motley Fool
04:43PM  Morgan Stanley and Vertex jump while McCormick slides Associated Press
04:33PM  Maxim Hikes Price Targets on 2 Biotech Stocks: AEterna Zentaris Inc. (USA) (AEZS), Vertex Pharmaceuticals Incorporated (VRTX) SmarterAnalyst
04:30PM  Biotech is moving beyond the 'disaster' of the past 2 years, says Michael Yee CNBC
04:26PM  Nasdaq Makes It Nine; This Industry's Surprise Rally Lifts S&P 500 Investor's Business Daily
04:22PM  Vertex Hits Record High On Results Of Cystic Fibrosis Trial Investor's Business Daily
04:18PM  GLOBAL MARKETS-World stocks tally 9th day of gains as earnings pick up Reuters
03:40PM  US STOCKS-S&P, Nasdaq at records as Vertex rallies; IBM slips Reuters
02:51PM  Jefferies' Michael Yee: Still a valuation call in biotech CNBC Videos
02:47PM  [$$] Vertex Shares Haven't Hit Their Apex The Wall Street Journal
02:30PM  Biotech Stocks On Verge Of Next Major Move Up Investopedia
02:01PM  GLOBAL MARKETS-World stocks climb for 9th day as earnings kick in Reuters
01:39PM  Vertex Wins Big in Mid-Stage Cystic Fibrosis Trial 24/7 Wall St.
01:10PM  US STOCKS-Tech lifts Nasdaq, S&P to record; IBM weighs on Dow Reuters
01:04PM  Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment TheStreet.com
01:02PM  Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today Motley Fool
12:53PM  Vertex: Up, Up, and Away! Barrons.com
12:49PM  Vertex leads biotech after cystic fibrosis drug data CNBC Videos
12:00PM  Here's Why Vertex Pharmaceuticals (VRTX) Soared Today Zacks
11:53AM  Story Stocks from Briefing.com Briefing.com
11:41AM  GLOBAL MARKETS-World stocks run win streak to 9 days as earnings heat up Reuters
10:54AM  Valeant Pharmaceuticals Intl Inc (VRX) In Good Debt Shape, Vertex Pharmaceuticals Incorporated (VRTX) Wows with Triple CF Combo Success SmarterAnalyst
10:54AM  The Zacks Analyst Blog Highlights: Apple, JPMorgan, Celgene, PayPal and Vertex Pharmaceuticals Zacks
10:53AM  Vertex Pharma shares surge 21% after cystic fibrosis study results leaves Wall Street 'speechless' CNBC
10:42AM  Vertex Shares Jump on Strong Trials of New Drugs The Wall Street Journal
10:26AM  Vertex (VRTX) Triple Combination CF Studies Data Positive Zacks
09:57AM  Vertex stock rockets to record, boosting market cap by $8 billion MarketWatch
09:43AM  Stocks Up: Nasdaq Takes New High, Morgan Stanley Breaks Out Investor's Business Daily
09:42AM  Biotech Movers: Vertex Continues to Move on Data for CF Regimen TheStreet.com
07:53AM  Vertex shares soar on positive cystic fibrosis trials CNBC Videos
07:22AM  How the Game of Krones could spice up your summer investments MarketWatch
06:47AM  Futures: This Biotech Goes Vertical; Tech Titan's 'Painful' Transition Investor's Business Daily
12:48AM  Vertex Reports Positive Data for New Cystic-Fibrosis Drugs The Wall Street Journal
Jul-18-17 06:09PM  Top Stock Reports for Apple, JPMorgan & Celgene Zacks
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SMITH IAN FEVP, CFO & COOAug 07Option Exercise77.314,250328,568120,138Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Option Exercise77.314,250328,568125,367Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Option Exercise77.311,28999,65317,923Aug 09 04:38 PM
SMITH IAN FEVP, CFO & COOAug 07Sale155.394,250660,415115,888Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Sale152.884,250649,740121,117Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Sale152.881,289197,06216,634Aug 09 04:38 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Option Exercise109.143,594392,249118,018Aug 04 04:42 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59231,139Aug 04 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise109.144,250463,845125,367Aug 04 04:53 PM
Parini MichaelEVP, CL&AOAug 03Sale155.722,330362,82828,809Aug 04 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Sale154.193,594554,149114,424Aug 04 04:42 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale155.724,250661,810121,117Aug 04 04:53 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,923Aug 04 04:36 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Option Exercise91.051,796163,526116,220Aug 04 04:42 PM
SMITH IAN FEVP, CFO & COOAug 02Option Exercise91.052,155196,213118,043Aug 04 04:48 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Sale154.131,796276,811114,424Aug 04 04:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale151.801,289195,67016,634Aug 04 04:36 PM
SMITH IAN FEVP, CFO & COOAug 02Sale154.172,155332,236115,888Aug 04 04:48 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Option Exercise83.362,125177,140123,242Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Option Exercise83.3686071,69017,494Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Option Exercise83.362,125177,140118,013Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Option Exercise45.1111,063499,052268,455Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Sale152.992,125325,104121,117Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Sale152.99860131,57116,634Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Sale152.882,125324,865115,888Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Sale152.8111,0631,690,552257,392Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Option Exercise131.892,125280,266133,592Jul 21 07:58 PM
Silva Paul MSVP & Corp ControllerJul 21Sale161.913,437556,49016,634Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 21Sale160.7210,3501,663,413115,888Jul 21 08:09 PM
Sachdev AmitEVP, CROJul 21Sale160.788,6251,386,69190,710Jul 21 08:07 PM
LEIDEN JEFFREY MCEO & PresidentJul 21Sale160.7432,2505,184,008257,392Jul 21 08:04 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 21Sale160.736,9001,109,022114,424Jul 21 08:02 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Sale161.2212,4752,011,271121,117Jul 21 07:58 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 19Option Exercise107.2589,4009,587,718220,867Jul 21 07:58 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Option Exercise84.4928,9792,448,338134,990Jul 21 08:00 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 19Option Exercise107.1438,6464,140,487161,157Jul 21 08:02 PM
Parini MichaelEVP, CL&AOJul 19Option Exercise89.4810,829968,97039,638Jul 21 08:05 PM
LEIDEN JEFFREY MCEO & PresidentJul 19Option Exercise46.56184,3748,584,824474,016Jul 21 08:04 PM
Sachdev AmitEVP, CROJul 19Option Exercise77.3120,0001,546,200119,335Jul 21 08:07 PM
Silva Paul MSVP & Corp ControllerJul 19Option Exercise75.9140,0063,036,87060,077Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 19Option Exercise84.11123,40010,379,726249,638Jul 21 08:09 PM
SMITH IAN FEVP, CFO & COOJul 19Sale161.00123,40019,867,400126,238Jul 21 08:09 PM
Silva Paul MSVP & Corp ControllerJul 19Sale161.0040,0066,440,96620,071Jul 21 08:10 PM
Sachdev AmitEVP, CROJul 19Sale161.0020,0003,220,00099,335Jul 21 08:07 PM
Parini MichaelEVP, CL&AOJul 19Sale161.0010,8291,743,46928,809Jul 21 08:05 PM
LEIDEN JEFFREY MCEO & PresidentJul 19Sale161.00184,37429,684,214289,642Jul 21 08:04 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 19Sale161.0039,8336,413,113121,324Jul 21 08:02 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Sale161.0028,9794,665,619106,011Jul 21 08:00 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 19Sale161.5489,40014,441,830131,467Jul 21 07:58 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 17Option Exercise96.8757355,507123,084Jul 19 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 17Sale129.8557374,402122,511Jul 19 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 03Option Exercise73.513,438252,727125,949Jul 06 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 03Sale127.803,438439,379122,511Jul 06 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 21Option Exercise96.875,157499,559127,668Jun 23 04:08 PM
Silva Paul MSVP & Corp ControllerJun 21Option Exercise83.362,577214,81922,648Jun 23 04:10 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 21Sale132.875,157685,211122,511Jun 23 04:08 PM
Silva Paul MSVP & Corp ControllerJun 21Sale133.362,577343,66920,071Jun 23 04:10 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 05Option Exercise72.147,500541,050113,511Jun 05 06:10 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 05Sale130.007,500975,000106,011Jun 05 06:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 02Option Exercise80.6757,3754,628,505188,842Jun 05 06:06 PM
LEIDEN JEFFREY MCEO & PresidentJun 02Option Exercise33.63147,1014,947,163436,743Jun 05 06:03 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 02Sale129.0257,3757,402,523131,467Jun 05 06:06 PM
Lee YuchunDirectorJun 02Sale128.441,323169,9264,847Jun 05 05:56 PM
Bhatia Sangeeta N.DirectorJun 02Sale128.441,176151,0453,953Jun 05 05:07 PM
LEIDEN JEFFREY MCEO & PresidentJun 02Sale129.50147,10119,049,580289,642Jun 05 06:03 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 01Option Exercise53.7413,594730,542145,061Jun 05 06:06 PM
Sachdev AmitEVP, CROJun 01Option Exercise51.7530,5001,578,375129,835Jun 05 06:08 PM
SMITH IAN FEVP, CFO & COOJun 01Option Exercise43.9998,5534,334,887224,791Jun 05 06:05 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 01Option Exercise96.875,155499,365127,666Jun 05 06:07 PM
Silva Paul MSVP & Corp ControllerJun 01Option Exercise77.313,867298,95823,938Jun 05 06:09 PM
Silva Paul MSVP & Corp ControllerJun 01Sale127.313,867492,30820,071Jun 05 06:09 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 01Sale126.875,155654,015122,511Jun 05 06:07 PM
Sachdev AmitEVP, CROJun 01Sale125.0030,5003,812,50099,335Jun 05 06:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 01Sale124.0013,5941,685,656131,467Jun 05 06:06 PM
SMITH IAN FEVP, CFO & COOJun 01Sale124.0098,55312,220,572126,238Jun 05 06:05 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale114.3718120,701106,011May 17 04:25 PM
SMITH IAN FEVP, CFO & COOMay 15Sale114.9229433,786126,238May 17 04:24 PM
Sachdev AmitEVP, CROMay 15Sale114.3711613,26799,335May 17 04:23 PM
Silva Paul MSVP & Corp ControllerMay 15Sale114.6427131,06720,071May 17 04:21 PM
Chodakewitz JeffreyEVP GMDA, CMOMay 02Option Exercise91.058,979817,538131,490May 04 08:51 AM
Chodakewitz JeffreyEVP GMDA, CMOMay 02Sale121.058,9791,086,908122,511May 04 08:51 AM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 28Option Exercise45.1128,3201,277,515159,567May 02 05:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOApr 28Option Exercise63.147,500473,550113,511May 02 05:18 PM
LEIDEN JEFFREY MCEO & PresidentApr 28Option Exercise31.51140,0344,412,253446,679Apr 28 04:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 28Sale119.5028,3203,384,240131,247May 02 05:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOApr 28Sale120.007,500900,000106,011May 02 05:18 PM
LEIDEN JEFFREY MCEO & PresidentApr 28Sale119.50157,20018,785,400289,479Apr 28 04:44 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 05Option Exercise73.518,021589,624130,532Apr 07 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 05Sale114.008,021914,394122,511Apr 07 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 03Option Exercise73.512,291168,411124,802Apr 05 04:55 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 03Sale108.852,291249,384122,511Apr 05 04:55 PM
Sachdev AmitEVP, CROMar 29Option Exercise44.4380,5003,576,273179,835Mar 31 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOMar 29Option Exercise73.5113,7501,010,763136,261Mar 31 04:08 PM
Silva Paul MSVP & Corp ControllerMar 29Option Exercise45.111,68876,14621,759Mar 31 04:09 PM
Sachdev AmitEVP, CROMar 29Sale107.6380,5008,664,56899,335Mar 31 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOMar 29Sale106.6513,7501,466,438122,511Mar 31 04:08 PM
Silva Paul MSVP & Corp ControllerMar 29Sale106.301,688179,43420,071Mar 31 04:09 PM
SMITH IAN FEVP, CFO & COOFeb 28Sale90.003,842345,780126,238Mar 02 04:15 PM
SMITH IAN FEVP, CFO & COOFeb 13Sale87.663,842336,790130,080Feb 15 04:41 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 13Sale87.675,122449,046122,511Feb 15 04:42 PM